AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18065071 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in movement goal for the second movement
Number of subjects: 20
Study 18065071 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate planning of sequential aiming movements
Number of subjects: 20
Study 18065071 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference due to practice organization and switching the task's goal
Number of subjects: 20
Study 15736608 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg or 400 mg of modafinil
Number of subjects: 15
Study 12393276 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN(‐)
Number of subjects: 65
Study 12393276 — intervention group
Group type: COMPARATOR
Intervention: rIFN(‐) + Ara‐C
Number of subjects: 65
Study 9523655 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT) using the Leo Microthermer system
Number of subjects: 67
Study 9523655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 67
Study 8732145 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese integrated medicine (CIM)
Number of subjects: 35
Study 8732145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 2649640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR4
Number of subjects: 14
Study 2649640 — intervention group
Group type: COMPARATOR
Intervention: Sinemet 25/100 (STD)
Number of subjects: 14
Study 413493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium cromoglycate solution
Number of subjects: 17
Study 31188727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase (PEG‐ASP)
Number of subjects: 598
Study 31188727 — intervention group
Group type: COMPARATOR
Intervention: Native Escherichia coli asparaginase (L‐ASP)
Number of subjects: 598
Study 31188727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal therapy (IT)
Number of subjects: 598
Study 31188727 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PEG-ASP antibodies
Number of subjects: 598
Study 31188727 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of angioedema with first reaction
Number of subjects: 598
Study 28430159 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight fucoidan (LMF) as a supplemental therapy to chemotarget agents
Number of subjects: 54
Study 28430159 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotarget agents only)
Number of subjects: 54
Study 26116078 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic wound infiltration (LAI)
Number of subjects: 0
Study 23396142 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-induced weight loss
Number of subjects: 32
Study 23396142 — intervention group
Group type: COMPARATOR
Intervention: Diet-induced weight loss
Number of subjects: 32
Study 21516182 — intervention group
Group type: EXPERIMENTAL
Intervention: Children (aged 8-13)
Number of subjects: 30
Study 21516182 — intervention group
Group type: COMPARATOR
Intervention: Young adults (aged 19-26)
Number of subjects: 30
Study 19450177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 19450177 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies with statistical adjustment for lead-time
Number of subjects: 0
Study 19450177 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies without statistical adjustment
Number of subjects: 0
Study 17934385 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 0
Study 17934385 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation and healthy lifestyle counseling
Number of subjects: 0
Study 17934385 — intervention group
Group type: EXPERIMENTAL
Intervention: Careful selection of medications and routine screening for cardiovascular risk factors
Number of subjects: 0
Study 15467597 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg b.i.d.)
Number of subjects: 0
Study 15467597 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 11408152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelisite capsule
Number of subjects: 8
Study 9562581 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-2
Number of subjects: 425
Study 9562581 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon alfa-2a
Number of subjects: 425
Study 9562581 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-2 plus interferon alfa-2a
Number of subjects: 425
Study 9562581 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 425
Study 9562581 — intervention group
Group type: COMPARATOR
Intervention: Toxic effects of therapy
Number of subjects: 425
Study 1820985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone alone
Number of subjects: 35
Study 1820985 — intervention group
Group type: EXPERIMENTAL
Intervention: VeMP regimen (VP‐16, Mitoxantrone, Prednisolone)
Number of subjects: 35
Study 7092136 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of metronidazole
Number of subjects: 131
Study 7092136 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline placebo
Number of subjects: 131
Study 7092136 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforated appendix cases
Number of subjects: 131
Study 7092136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (metronidazole and placebo)
Number of subjects: 131
Study 30681559 — intervention group
Group type: COMPARATOR
Intervention: Methylene blue localization group (n=47)
Number of subjects: 79
Study 30681559 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified localization group (n=32)
Number of subjects: 79
Study 28993069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination A (silicone-hydrogel CLs)
Number of subjects: 20
Study 28993069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination B (silicone-hydrogel CLs)
Number of subjects: 20
Study 25775634 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied to a representative plaque for 9 months
Number of subjects: 25
Study 25775634 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied to a control plaque for 9 months
Number of subjects: 25
Study 24216543 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF) with synbiotics
Number of subjects: 145
Study 24216543 — intervention group
Group type: COMPARATOR
Intervention: Commercially available AAF
Number of subjects: 145
Study 22509860 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection device
Number of subjects: 2783
Study 22509860 — intervention group
Group type: COMPARATOR
Intervention: Control (PCI alone)
Number of subjects: 2783
Study 20224285 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula F plus donepezil
Number of subjects: 52
Study 20224285 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus donepezil
Number of subjects: 52
Study 18765643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 60
Study 18765643 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 60
Study 18765643 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 60
Study 15962065 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of ketoprofen 100 mg (Group C)
Number of subjects: 19
Study 15962065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of tenoxicam 40 mg (Group T)
Number of subjects: 19
Study 15962065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of physiological serum 0.9% (Group F)
Number of subjects: 19
Study 14756017 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training (daily exercise program for 21 +/- 10 days)
Number of subjects: 74
Study 10477986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain‐Free (oxalate‐containing pre‐polymerized resin suspension)
Number of subjects: 10
Study 10477986 — intervention group
Group type: EXPERIMENTAL
Intervention: DentinBloc (0.7% fluoride solution)
Number of subjects: 10
Study 10477986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 10
Study 1372668 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement activating membrane
Number of subjects: 0
Study 1372668 — intervention group
Group type: COMPARATOR
Intervention: Non-complement activating membrane
Number of subjects: 0
Study 3834830 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppositories containing sodium salicylate and Brij 35
Number of subjects: 6
Study 3834830 — intervention group
Group type: COMPARATOR
Intervention: Suppositories without adjuvants
Number of subjects: 6
Study 3834830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate
Number of subjects: 6
Study 3834830 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppositories (general)
Number of subjects: 6
Study 31578173 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide (four 60 mg tablets, once daily)
Number of subjects: 1052
Study 31578173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study 29782276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 27395
Study 27310958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 μg
Number of subjects: 60
Study 27310958 — intervention group
Group type: COMPARATOR
Intervention: Control group (spinal anesthesia with bupivacaine supplemented with normal saline)
Number of subjects: 60
Study 24383843 — intervention group
Group type: EXPERIMENTAL
Intervention: imatinib 800 mg daily (IM800)
Number of subjects: 153
Study 24383843 — intervention group
Group type: COMPARATOR
Intervention: imatinib 400 mg daily (IM400)
Number of subjects: 153
Study 22828088 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan and moxonidine
Number of subjects: 42
Study 22828088 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumethiazide and amlodipine
Number of subjects: 42
Study 19943990 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time (actigraphic measurement)
Number of subjects: 45
Study 19943990 — intervention group
Group type: EXPERIMENTAL
Intervention: Time awake after initial sleep onset (actigraphic measurement)
Number of subjects: 45
Study 17611565 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT)
Number of subjects: 421
Study 17611565 — intervention group
Group type: EXPERIMENTAL
Intervention: Geno-identical allogeneic SCT
Number of subjects: 421
Study 17611565 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions
Number of subjects: 421
Study 17611565 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated donor transplantation
Number of subjects: 421
Study 17611565 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 421
Study 16163089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative-pressure therapy with no interface dressing
Number of subjects: 40
Study 16163089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative-pressure therapy with Vaseline-impregnated gauze
Number of subjects: 40
Study 16163089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative-pressure therapy with nonadherent silicone dressing
Number of subjects: 40
Study 16163089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative-pressure therapy with mylar polyester film dressing
Number of subjects: 40
Study 12393106 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin prophylaxis and epidural analgesia
Number of subjects: 52
Study 10102328 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorimetric end-tidal CO2 (ETCO2) detector (EASY CAP)
Number of subjects: 121
Study 7586476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin hydrogel lenses (0.04 mm, 67% water content)
Number of subjects: 20
Study 7586476 — intervention group
Group type: COMPARATOR
Intervention: Standard thickness hydrogel lenses (0.12 mm)
Number of subjects: 20
Study 7586476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin hydrogel lenses
Number of subjects: 20
Study 7586476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin hydrogel lenses and Standard thickness lenses
Number of subjects: 20
Study 1874490 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodiol therapy
Number of subjects: 31
Study 1874490 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar chenodiol doses, no liver injury)
Number of subjects: 31
Study 1874490 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (n = 45)
Number of subjects: 31
Study 7318640 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 19
Study 7318640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31070709 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8273
Number of subjects: 530
Study 31070709 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib/gefitinib
Number of subjects: 530
Study 27867080 — intervention group
Group type: EXPERIMENTAL
Intervention: Rom-PLIF (robot-assisted, minimally invasive posterior lumbar interbody fusion)
Number of subjects: 78
Study 27867080 — intervention group
Group type: COMPARATOR
Intervention: Cop-PLIF (conventional, freehand, open approach posterior lumbar interbody fusion)
Number of subjects: 78
Study 26491868 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with radiological OA and 'mild' overall symptoms on the WOMAC score
Number of subjects: 389
Study 26491868 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with clinical OA and 'severe' overall symptoms
Number of subjects: 389
Study 23474008 — intervention group
Group type: EXPERIMENTAL
Intervention: Far infrared therapy (40 minutes, 3 times weekly for a year)
Number of subjects: 122
Study 23474008 — intervention group
Group type: EXPERIMENTAL
Intervention: Far infrared therapy
Number of subjects: 122
Study 23474008 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study 21357380 — intervention group
Group type: EXPERIMENTAL
Intervention: High isoflavone intake (>16.3 mg isoflavones)
Number of subjects: 3088
Study 21357380 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing isoflavone intake
Number of subjects: 3088
Study 19303721 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 226
Study 17050010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary stem cell therapy
Number of subjects: 46
Study 17050010 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 46
Study 15499530 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum from vaccinated mothers
Number of subjects: 16
Study 15499530 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 16
Study 11564574 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL) provided
Number of subjects: 800
Study 11564574 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflet absent)
Number of subjects: 800
Study 9973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI; 25-37.5 mg)
Number of subjects: 130
Study 9973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (MOCLO; 450-600 mg)
Number of subjects: 130
Study 9973149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 7977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 14124
Study 7977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose t-PA
Number of subjects: 14124
Study 7977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated dose t-PA
Number of subjects: 14124
Study 7977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC)
Number of subjects: 14124
Study 7977094 — intervention group
Group type: COMPARATOR
Intervention: t-PA
Number of subjects: 14124
Study 7977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 14124
Study 2908486 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Number of subjects: 10
Study 2908486 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 10
Study 2908486 — intervention group
Group type: COMPARATOR
Intervention: Control saline solution
Number of subjects: 10
Study 2908486 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine: aqueous solution (Hsol)
Number of subjects: 10
Study 2908486 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine: prick test (Hprick)
Number of subjects: 10
Study 30101416 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) solution
Number of subjects: 0
Study 30101416 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) + hyaluronic acid (HA) + antidiscoloration system (ADS)
Number of subjects: 0
Study 27531660 — intervention group
Group type: EXPERIMENTAL
Intervention: iTClamp
Number of subjects: 13
Study 27531660 — intervention group
Group type: COMPARATOR
Intervention: Combat Application Tourniquet (CAT)
Number of subjects: 13
Study 23549653 — intervention group
Group type: EXPERIMENTAL
Intervention: Online evidence-based patient information (EBPI)
Number of subjects: 0
Study 23549653 — intervention group
Group type: COMPARATOR
Intervention: Standard patient information
Number of subjects: 0
Study 23951692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg/kg over 10 minutes at anesthesia induction, followed by 0.4 to 0.8 microg/kg per hour infusion during maintenance
Number of subjects: 66
Study 23951692 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 1 microg/kg over 1 minute at anesthesia induction, followed by 0.2 to 0.4 microg/kg per minute infusion during maintenance
Number of subjects: 66
Study 19933801 — intervention group
Group type: EXPERIMENTAL
Intervention: S-013420 (EDP-420)
Number of subjects: 28
Study 17967217 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg daily)
Number of subjects: 430
Study 17967217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 16004022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox nail lacquer once daily for 48 weeks plus 4 weeks of terbinafine 250 mg/day, followed by 4 weeks of rest (no terbinafine), then another 4 weeks of terbinafine 250 mg/day (PLs)
Number of subjects: 73
Study 16004022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox nail lacquer once daily for 48 weeks plus terbinafine 250 mg/day for 12 weeks (PL12)
Number of subjects: 73
Study 16004022 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine 250 mg/day for 12 weeks (L12)
Number of subjects: 73
Study 12855874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (I degrees FN)
Number of subjects: 35
Study 12855874 — intervention group
Group type: COMPARATOR
Intervention: Damage control orthopedic surgery and external fixation (DCO I degrees Ex.fix.)
Number of subjects: 35
Study 12855874 — intervention group
Group type: COMPARATOR
Intervention: Damage control orthopedic surgery and external fixation (DCO II degrees FN)
Number of subjects: 35
Study 9892253 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (0.8 g/kg per day)
Number of subjects: 22
Study 9050688 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.75 mg
Number of subjects: 13
Study 9050688 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 13
Study 1931396 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms kg‐1 i.v. administered over 20 min
Number of subjects: 20
Study 1931396 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 20
Study 399527 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin (PGI2)
Number of subjects: 10
Study 31001633 — intervention group
Group type: EXPERIMENTAL
Intervention: 15/50 VLP vaccine formulation (15 µg of GI.1 and 50 µg of GII.4c VLPs)
Number of subjects: 454
Study 31001633 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 VLP vaccine formulation (50 µg of GI.1 and 50 µg of GII.4c VLPs)
Number of subjects: 454
Study 31001633 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory probe vaccination (15 µg each of GI.1 and GII.4c VLPs with Al(OH)3)
Number of subjects: 454
Study 31001633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 454
Study 28573476 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction radiotherapy (8 Gy × 1 fraction)
Number of subjects: 101
Study 28573476 — intervention group
Group type: COMPARATOR
Intervention: Multifraction radiotherapy (3 Gy × 10 fractions)
Number of subjects: 101
Study 25403645 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F‐PCC 50 IU/kg
Number of subjects: 110
Study 25403645 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F‐PCC 25 IU/kg
Number of subjects: 110
Study 25403645 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F‐PCC 10 IU/kg
Number of subjects: 110
Study 25403645 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban 60 mg
Number of subjects: 110
Study 23276801 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing (WB) exercise
Number of subjects: 29
Study 23276801 — intervention group
Group type: COMPARATOR
Intervention: Nonweight-bearing (NWB) exercise
Number of subjects: 29
Study 20530591 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐methylparatyrosine
Number of subjects: 10
Study 20530591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19861667 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology
Number of subjects: 89784
Study 19861667 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pap test
Number of subjects: 89784
Study 17364311 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg)
Number of subjects: 120
Study 17364311 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (200 microg)
Number of subjects: 120
Study 15160251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft patients (UCLP and BCLP)
Number of subjects: 23
Study 15160251 — intervention group
Group type: COMPARATOR
Intervention: Non-cleft controls
Number of subjects: 23
Study 11817713 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week progressive high-intensity strength training (HIST) program
Number of subjects: 30